Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vera Therapeutics (VERA), Crinetics Pharmaceuticals (CRNX) and Revolution Medicines (RVMD).TipRanks Welcomes a New ETF – NYSE:RANK TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE. RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Vera Therapeutics (VERA)
In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Vera Therapeutics, with a price target of $90.00. The company’s shares closed last Friday at $42.00.
According to TipRanks.com, Katkhuda is a 5-star analyst with an average return of 32.8% and a 58.6% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., MoonLake Immunotherapeutics, and Amylyx Pharmaceuticals Inc.
Currently, the analyst consensus on Vera Therapeutics is a Strong Buy with an average price target of $82.38, a 95.4% upside from current levels. In a report issued on July 7, TD Cowen also maintained a Buy rating on the stock with a $78.00 price target.
